HIV clinical stages and lower extremity arterial disease among HIV infected outpatients in Burundi

Chronic disease of people living with human immunodeficiency virus (HIV) infection are now approaching those of the general population. Previous, in vitro studies shown that HIV causes arterial injuries resulting in inflammation and atherosclerosis but direct relationship between HIV infection clinical stages and lower extremity arterial disease (LEAD) remain controversial. No study assessed, with an accurate method, both the prevalence of LEAD and the influence of HIV severity on LEAD in HIV outpatients in Central Africa. A cross-sectional study was conducted among 300 HIV-infected outpatients, aged >= 40 years in Bujumbura, Burundi. All patients underwent ankle-brachial index (ABI) measurement and LEAD was diagnosed by ABI <= 0.9. The prevalence of LEAD was 17.3% (CI 95% 13.2-22.1). The mean age was 49.6 +/- 7.1 years. On multivariable analysis, factors associated with LEAD were hypertension (OR=2.42; 95% CI 1.10-5.80), and stage IV HIV clinical infection (OR=4.92, 95% CI 1.19-20.36). This is the first study performed on a large HIV population in Central Africa, reporting high LEAD prevalence. It underlines the influence of HIV infection on peripheral atherosclerosis at latest clinical stages and the need for LEAD screening in HIV-infected patients.

Automated summary

This study conducted in Burundi among 300 HIV-infected outpatients aged >=40 years found a LEAD prevalence of 17.3%, with factors associated with LEAD including hypertension and stage IV HIV clinical infection. This is the first large study in Central Africa reporting a high prevalence of LEAD among HIV patients, highlighting the influence of HIV on peripheral atherosclerosis at later clinical stages and the need for LEAD screening in this population.